DeepMed Research

Dalpiciclib

Generic Name: Dalpiciclib

Drug Type: Small Molecule

Chemical Formula: C_₂₅H_₃₀N_₆O_₂

CAS Number: 1637781-04-4

Unique Ingredient Identifier: 5ZHA5P4PFX

Clinical Trials

Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy

Phase 2

Recruiting

Conditions: Breast Neoplasm
HER2-positive Breast Cancer
HER2-negative Breast Cancer
Hormone Receptor Positive Tumor
Breast Cancer
Breast Tumors
Hormone Receptor Negative Tumor
Triple-Negative Breast Cancer (TNBC)
Locally Advanced Breast Cancer
Early-stage Breast Cancer

Interventions: Drug: Nab paclitaxel
Drug: Camrelizumab
Drug: Pyrotinib
Drug: SHR-A1811
Drug: SHR-A1921
Drug: Pertuzumab
Drug: SHR-1316
Drug: Dalpiciclib
Drug: Trastuzumab
Drug: Goserelin
Drug: Carboplatin
Drug: Apatinib
Drug: Letrozole
Drug: Famitinib
Drug: Epirubicin
Drug: Cyclophosphamide
Drug: Fluzoparib

First Posted Date: 2022-10-17

Last Posted Date: 2024-12-27

Lead Sponsor: Fudan University

Target Recruit Count: 716

Registration Number: NCT05582499

Locations: 🇨🇳
Fudan University Shanghai Cancer Center Shanghai, China, 200032, Shanghai, Shanghai, China

Exploring Whether Disease-free Intervals Can Guide Endocrine Combined Targeted Therapy for ER+/HER2+ Advanced Breast Cancer (T-sunflower)

Phase 2

Not yet recruiting

Conditions: Metastatic Breast Cancer

Interventions: Drug: Trastuzumab
Drug: pyrotinib
Drug: Dalpiciclib
Drug: fulvestrant

First Posted Date: 2022-10-13

Last Posted Date: 2022-10-13

Lead Sponsor: Fudan University

Target Recruit Count: 126

Registration Number: NCT05577923

Locations: 🇨🇳
Fudan University Shanghai Cancer Center Shanghai, China, 200032, Shanghai, Shanghai, China

Efficacy and Safety of Dalpiciclib in Hormone Receptor-positive Advanced Breast Cancer

Not yet recruiting

Conditions: Breast Cancer

Interventions: Drug: Dalpiciclib

First Posted Date: 2022-10-13

Last Posted Date: 2022-10-13

Lead Sponsor: Hebei Medical University Fourth Hospital

Target Recruit Count: 420

Registration Number: NCT05578053

Dalpiciclib, Fulvestrant, Trastuzumab and Pertuzumab in HR Positive, HER2 Positive Metastatic Breast Cancer

Phase 1

Active, not recruiting

Conditions: Breast Cancer

Interventions: Drug: Dalpiciclib
Drug: Fulvestrant
Drug: Pertuzumab
Drug: Trastuzumab

First Posted Date: 2022-10-12

Last Posted Date: 2024-02-26

Lead Sponsor: Fudan University

Target Recruit Count: 72

Registration Number: NCT05574881

Locations: 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China

Study of SHR6390 in Renal Insufficiency and Healthy Subjects

Phase 1

Recruiting

Conditions: Breast Cancer

Interventions: Drug: SHR6390

First Posted Date: 2022-08-25

Last Posted Date: 2023-03-10

Lead Sponsor: Jiangsu HengRui Medicine Co., Ltd.

Target Recruit Count: 30

Registration Number: NCT05515289

Locations: 🇨🇳
Zhongda Hospital Southesat University, Nanjing, Jiangsu, China

Neoadjuvant Dalpiciclib Plus Letrozole for HR+/HER2- Breast Cancer

Phase 2

Conditions: Breast Cancer

Interventions: Drug: dalpiciclib plus letrozole

First Posted Date: 2022-08-23

Last Posted Date: 2022-08-23

Lead Sponsor: The Affiliated Hospital of Qingdao University

Target Recruit Count: 35

Registration Number: NCT05512416

Dalpiciclib Combined With Letrozole in Neoadjuvant Treatment of Stage Ⅱ-Ⅲ HR-positive/HER2-negative Breast Cancer

Phase 2

Conditions: Solid Tumor

Interventions: Drug: Dalpiciclib

First Posted Date: 2022-08-23

Last Posted Date: 2022-08-23

Lead Sponsor: Hebei Medical University Fourth Hospital

Target Recruit Count: 30

Registration Number: NCT05512780

mFOLFOX6 Combined With Dalpiciclib in Patients With Metastatic Colorectal Cancer

Phase 2

Recruiting

Conditions: Advanced/Metastatic Colorectal Cancer

Interventions: Drug: Dalpiciclib
Drug: Oxaliplatin injection
Drug: Calcium folinate
Drug: 5-fluorouracil

First Posted Date: 2022-07-29

Last Posted Date: 2023-02-28

Lead Sponsor: Sixth Affiliated Hospital, Sun Yat-sen University

Target Recruit Count: 18

Registration Number: NCT05480280

Locations: 🇨🇳
Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China

Mecapegfilgrastim for the Prevention of Dalpiciclib -Induced Neutropenia in Advanced Breast Cancer

Phase 2

Active, not recruiting

Conditions: Metastatic Breast Cancer

Interventions: Drug: Mecapegfilgrastim
Drug: exemestane, fulvestrant, letrozole, tamoxifen
Drug: dalpiciclib

First Posted Date: 2022-07-19

Last Posted Date: 2025-05-14

Lead Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Target Recruit Count: 132

Registration Number: NCT05463601

Locations: 🇨🇳
中山大学中山纪念医院, Guangzhou, Guangdong, China

The Efficacy and Safety of Dalpiciclib Plus Endocrine Therapy in HR-positive / HER2-negative Advanced Breast Cancer Patients With Visceral Crisis

Phase 2

Not yet recruiting

Conditions: Advanced Breast Cancer

Interventions: Drug: Dalpiciclib in combination with endocrine therapy by Physicians choice

First Posted Date: 2022-06-24

Last Posted Date: 2022-06-24

Lead Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Target Recruit Count: 53

Registration Number: NCT05431504

Locations: 🇨🇳
Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, Beijing, China

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy